Tuberculosis, Internal medicine, Immunology, Mycobacterium tuberculosis and Antibacterial agent are his primary areas of study. His biological study spans a wide range of topics, including Regimen, Respiratory disease and Randomized controlled trial. His work carried out in the field of Internal medicine brings together such families of science as Pyrazinamide, Rifampicin, Isoniazid, Surgery and Gastroenterology.
The study incorporates disciplines such as Retrospective cohort study, Acquired immunodeficiency syndrome and Cohort study in addition to Immunology. His Mycobacterium tuberculosis research is multidisciplinary, incorporating elements of Interleukin and Disease. The various areas that John L. Johnson examines in his Antibacterial agent study include Moxifloxacin, Pharmacokinetics, Pharmacology and Intensive care.
John L. Johnson mainly focuses on Tuberculosis, Internal medicine, Immunology, Mycobacterium tuberculosis and Sputum. His Tuberculosis research focuses on Clinical trial and how it connects with Drug. His studies in Internal medicine integrate themes in fields like Gastroenterology, Pyrazinamide, Rifampicin and Surgery.
In his study, which falls under the umbrella issue of Immunology, Latent tuberculosis is strongly linked to Virology. John L. Johnson has researched Mycobacterium tuberculosis in several fields, including Respiratory disease, Microbiology and Vaccination. In his study, Pharmacokinetics is strongly linked to Antibiotics, which falls under the umbrella field of Sputum.
John L. Johnson mainly investigates Tuberculosis, Internal medicine, Mycobacterium tuberculosis, Immunology and Sputum. His study in Tuberculosis is interdisciplinary in nature, drawing from both Clinical trial, Young adult, Regimen, Disease and Prospective cohort study. He interconnects Surgery, Ethambutol and Drug in the investigation of issues within Internal medicine.
His studies deal with areas such as Gastroenterology, T cell, Coinfection and Isoniazid as well as Mycobacterium tuberculosis. His work on Vaccination, CD8 and Inflammation as part of general Immunology study is frequently connected to Biomarker discovery, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Sputum study incorporates themes from Mycobacterium tuberculosis complex and Agar.
John L. Johnson mostly deals with Tuberculosis, Internal medicine, Immunology, Mycobacterium tuberculosis and Randomized controlled trial. His research in Tuberculosis is mostly concerned with Isoniazid. His Internal medicine research incorporates elements of Sputum and Surgery.
His Immunology study integrates concerns from other disciplines, such as Prospective cohort study and Disease. His Mycobacterium tuberculosis research is multidisciplinary, relying on both CD8, Immune system and Vaccination. His Randomized controlled trial research includes themes of Infectious disease, Regimen, Drug resistance and Dosing.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus
Whalen Cc;Johnson Jl;Okwera A;Hom Dl.
The New England Journal of Medicine (1997)
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
William J. Burman;Stefan Goldberg;John L. Johnson;Grace Muzanye.
American Journal of Respiratory and Critical Care Medicine (2006)
Depressed T-Cell Interferon-γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy
Christina S. Hirsch;Zahra Toossi;Catherine Othieno;John L Johnson.
The Journal of Infectious Diseases (1999)
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman;John L. Johnson;Stefan Goldberg;Grace Muzanye.
American Journal of Respiratory and Critical Care Medicine (2009)
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
John L. Johnson;D. J. Hadad;W. H. Boom;C. L. Daley.
International Journal of Tuberculosis and Lung Disease (2006)
A study of the safety immunology virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
Robert S. Wallis;Peter Kyambadde;John L. Johnson;Libby Horter.
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.
Christopher C. Whalen;Peter Nsubuga;Alphonse Okwera;John L. Johnson.
Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis
Charles A. Peloquin;David Jamil Hadad;Lucilia Pereira Dutra Molino;Moises Palaci.
Antimicrobial Agents and Chemotherapy (2008)
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
John L. Johnson;Alphonse Okwera;David L. Hom;Harriet Mayanja.
Infection and disease among household contacts of patients with multidrug-resistant tuberculosis.
L Teixeira;M D Perkins;J L Johnson;R Keller.
International Journal of Tuberculosis and Lung Disease (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: